{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T18:41:49Z","timestamp":1784140909015,"version":"3.55.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.ijrobp.2025.06.3858","type":"journal-article","created":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T17:16:49Z","timestamp":1759339009000},"page":"1259-1268","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Gallium-68-Labeled Prostate-Specific Membrane Antigen Positron Emission Tomography\/Computed Tomography Response in Pelvic Node-Positive Prostate Cancer After Definitive Radiation Therapy: Prognostic Implications"],"prefix":"10.1016","volume":"123","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2742-9021","authenticated-orcid":false,"given":"Cem","family":"Onal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ozan Cem","family":"Guler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nese","family":"Torun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birhan","family":"Demirhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aysenur","family":"Elmali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pervin","family":"Hurmuz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melek","family":"Yavuz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew P.","family":"Deek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phuoc T.","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet","family":"Reyhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vedang","family":"Murthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2025.06.3858_bib0001","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.eururo.2020.09.042","article-title":"EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer-2020 update. Part 1: screening, diagnosis, and local treatment with curative intent","volume":"79","author":"Mottet","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.ijrobp.2025.06.3858_bib0002","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer-2024 update. Part 1: screening, diagnosis, and local treatment with curative intent","volume":"86","author":"Cornford","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.ijrobp.2025.06.3858_bib0003","doi-asserted-by":"crossref","first-page":"e461","DOI":"10.1016\/j.clgc.2023.05.010","article-title":"Cancer-specific mortality differences in specimen-confined radical prostatectomy patients according to lymph node invasion","volume":"21","author":"Barletta","year":"2023","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.ijrobp.2025.06.3858_bib0004","doi-asserted-by":"crossref","first-page":"105.e19","DOI":"10.1016\/j.urolonc.2022.10.021","article-title":"Oncologic outcomes of patients with lymph node invasion at prostatectomy and post-prostatectomy biochemical persistence","volume":"41","author":"Perera","year":"2023","journal-title":"Urol Oncol"},{"key":"10.1016\/j.ijrobp.2025.06.3858_bib0005","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ctrv.2016.03.016","article-title":"Prognostic value of biochemical response to neoadjuvant androgen deprivation before external beam radiotherapy for prostate cancer: a systematic review of the literature","volume":"46","author":"Zilli","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ijrobp.2025.06.3858_bib0006","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0022-5347(05)64559-4","article-title":"Prognostic significance of the nadir prostate specific antigen level after hormone therapy for prostate cancer","volume":"168","author":"Kwak","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.ijrobp.2025.06.3858_bib0007","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","article-title":"Prostate-specific membrane antigen pet-ct in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study","volume":"395","author":"Hofman","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ijrobp.2025.06.3858_bib0008","article-title":"Prostate-specific membrane antigen PET response associates with metastasis-free survival after stereotactic ablative radiation in oligometastatic prostate cancer","volume":"9","author":"Sutera","year":"2024","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2025.06.3858_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2024.110443","article-title":"Machine learning predicts conventional imaging metastasis-free survival (MFS) for oligometastatic castration-sensitive prostate cancer (omCSPC) using prostate-specific membrane antigen (PSMA) PET radiomics","volume":"199","author":"Cao","year":"2024","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2025.06.3858_bib0010","doi-asserted-by":"crossref","first-page":"7812","DOI":"10.7150\/thno.47251","article-title":"Analysis of PSMA expression and outcome in patients with advanced Prostate Cancer receiving 177Lu-PSMA-617 Radioligand Therapy","volume":"10","author":"Seifert","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.ijrobp.2025.06.3858_bib0011","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.2967\/jnumed.121.263006","article-title":"68Ga-PSMA PET\/CT for response assessment and outcome prediction in metastatic prostate cancer patients treated with taxane-based chemotherapy","volume":"63","author":"Shagera","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ijrobp.2025.06.3858_bib0012","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.2967\/jnumed.120.259069","article-title":"Prospective, single-arm trial evaluating changes in uptake patterns on prostate-specific membrane antigen-targeted 18F-DCFPyL PET\/CT in patients with castration-resistant prostate cancer starting abiraterone or enzalutamide","volume":"62","author":"Zukotynski","year":"2021","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ijrobp.2025.06.3858_bib0013","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.2967\/jnumed.122.265368","article-title":"The association between [68Ga]PSMA PET\/CT response and biochemical progression in patients with high-risk prostate cancer receiving neoadjuvant therapy","volume":"64","author":"Chen","year":"2023","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ijrobp.2025.06.3858_bib0014","doi-asserted-by":"crossref","first-page":"3755","DOI":"10.1007\/s00259-023-06321-1","article-title":"The significance of metabolic response to neoadjuvant androgen deprivation therapy detected with [(68)Ga]Ga-PSMA-PET\/CT in high-risk prostate cancer patients treated with definitive radiotherapy","volume":"50","author":"Onal","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.ijrobp.2025.06.3858_bib0015","doi-asserted-by":"crossref","first-page":"e383","DOI":"10.1097\/RLU.0000000000005284","article-title":"Evaluation of treatment outcomes of prostate cancer patients with lymph node metastasis treated with definitive radiotherapy: comparative analysis of PSMA PET\/CT and conventional imaging","volume":"49","author":"Onal","year":"2024","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.ijrobp.2025.06.3858_bib0016","doi-asserted-by":"crossref","first-page":"20130617","DOI":"10.1259\/bjr.20130617","article-title":"Simultaneous integrated boost to intraprostatic lesions using different energy levels of intensity-modulated radiotherapy and volumetric-arc therapy","volume":"87","author":"Onal","year":"2014","journal-title":"Br J Radiol"},{"key":"10.1016\/j.ijrobp.2025.06.3858_bib0017","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1002\/pros.24558","article-title":"Treatment outcomes of simultaneous integrated boost to intraprostatic lesions with external beam radiotherapy in localized prostate cancer patients","volume":"83","author":"Onal","year":"2023","journal-title":"Prostate"},{"key":"10.1016\/j.ijrobp.2025.06.3858_bib0018","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.ijrobp.2020.08.034","article-title":"NRG Oncology updated international consensus atlas on pelvic lymph node volumes for intact and postoperative prostate cancer","volume":"109","author":"Hall","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.06.3858_bib0019","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ijrobp.2023.07.020","article-title":"Consensus delineation guidelines for pelvic lymph node radiation therapy of prostate cancer: on behalf of the Francophone Group of Urological Radiation Therapy (GFRU)","volume":"118","author":"De Hertogh","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.06.3858_bib0020","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.ijrobp.2006.04.029","article-title":"Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference","volume":"65","author":"Roach","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.06.3858_bib0021","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s00259-020-04934-4","article-title":"Consensus statements on PSMA PET\/CT response assessment criteria in prostate cancer","volume":"48","author":"Fanti","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.ijrobp.2025.06.3858_bib0022","doi-asserted-by":"crossref","first-page":"837","DOI":"10.2307\/2531595","article-title":"Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach","volume":"44","author":"DeLong","year":"1988","journal-title":"Biometrics"},{"key":"10.1016\/j.ijrobp.2025.06.3858_bib0023","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20160764","article-title":"Radiotherapy response evaluation using FDG PET-CT-established and emerging applications","volume":"90","author":"Cliffe","year":"2017","journal-title":"Br J Radiol"},{"key":"10.1016\/j.ijrobp.2025.06.3858_bib0024","doi-asserted-by":"crossref","first-page":"88","DOI":"10.2967\/jnumed.108.054205","article-title":"18F-FDG PET and PET\/CT in the evaluation of cancer treatment response","volume":"50","author":"Ben-Haim","year":"2009","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ijrobp.2025.06.3858_bib0025","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S1470-2045(22)00605-2","article-title":"PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial","volume":"23","author":"Buteau","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2025.06.3858_bib0026","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1002\/pros.24775","article-title":"Impact of definitive radiotherapy on metabolic response measured with (68)Ga-PSMA-PET\/CT in patients with intermediate-risk prostate cancer","volume":"84","author":"Onal","year":"2024","journal-title":"Prostate"},{"key":"10.1016\/j.ijrobp.2025.06.3858_bib0027","first-page":"14","article-title":"Prognostic value of metabolic, volumetric and textural parameters of baseline [(18)f]fdg pet\/ct in early triple-negative breast cancer","author":"Bouron","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ijrobp.2025.06.3858_bib0028","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s13014-023-02224-5","article-title":"Prognostic value of metabolic, volumetric and textural parameters of baseline [18F]FDG PET\/CT in early triple-negative breast cancer","volume":"18","author":"Xia","year":"2023","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2025.06.3858_bib0029","first-page":"107","article-title":"Androgen deprivation with or without radiation therapy for clinically node-positive prostate cancer","author":"Lin","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ijrobp.2025.06.3858_bib0030","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1001\/jamaoncol.2015.4350","article-title":"Failure-free survival and radiotherapy in patients with newly diagnosed nonmetastatic prostate cancer: data from patients in the control arm of the STAMPEDE trial","volume":"2","author":"James","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ijrobp.2025.06.3858_bib0031","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1016\/S0140-6736(18)32486-3","article-title":"Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial","volume":"392","author":"Parker","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.ijrobp.2025.06.3858_bib0032","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.ijrobp.2022.07.011","article-title":"Common iliac node-positive prostate cancer treated with curative radiation therapy: N1 or M1a?","volume":"114","author":"Chopade","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.06.3858_bib0033","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109746","article-title":"Impact of prostate radiotherapy on survival outcomes in clinically node-positive prostate cancer: a multicentre retrospective analysis","volume":"186","author":"Elumalai","year":"2023","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2025.06.3858_bib0034","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.25143","article-title":"Analysis of radiation facility volume and survival in men with lymph node-positive prostate cancer treated with radiation and androgen deprivation therapy","volume":"3","author":"Patel","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ijrobp.2025.06.3858_bib0035","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.eururo.2024.09.017","article-title":"Management of patients with advanced prostate cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC)","volume":"87","author":"Gillessen","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.ijrobp.2025.06.3858_bib0036","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s40644-020-0290-9","article-title":"Psma pet for primary lymph node staging of intermediate and high-risk prostate cancer: an expedited systematic review","volume":"20","author":"Petersen","year":"2020","journal-title":"Cancer Imaging"},{"key":"10.1016\/j.ijrobp.2025.06.3858_bib0037","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1002\/pros.23812","article-title":"Comparison of preoperative locoregional Ga-68 PSMA-11 PET-CT and mp-MRI results with postoperative histopathology of prostate cancer","volume":"79","author":"Yilmaz","year":"2019","journal-title":"Prostate"},{"key":"10.1016\/j.ijrobp.2025.06.3858_bib0038","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1007\/s00261-024-04188-w","article-title":"Prostate-specific membrane antigen-positron emission tomography (PSMA-PET) of prostate cancer: current and emerging applications","volume":"49","author":"Moran","year":"2024","journal-title":"Abdom Radiol (NY)"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301625044967?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301625044967?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T06:03:20Z","timestamp":1779084200000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301625044967"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S0360301625044967"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2025.06.3858","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gallium-68-Labeled Prostate-Specific Membrane Antigen Positron Emission Tomography\/Computed Tomography Response in Pelvic Node-Positive Prostate Cancer After Definitive Radiation Therapy: Prognostic Implications","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2025.06.3858","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}